2 news items
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise
ADAP
3 Jun 24
@adaptimmune.comMedia RelationsDana Lynch, Senior Director of Corporate CommunicationsM: +1 267 990 1217
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
ADAP
GLPG
30 May 24
Juli.Miller@adaptimmune.comMedia RelationsDana Lynch, Senior Director of Corporate Communications
- Prev
- 1
- Next